{
  "id": 2257075,
  "title": "Surgery Partners director Teresa DeLuca buys $161,212 in stock",
  "url": "https://urgent.news/2026/08/21/surgery-partners-director-teresa-deluca-buys-161-212-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T00:01:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/surgery-partners-director-teresa-deluca-buys-161212-in-stock-93CH-4870655"
  },
  "original_language": "en",
  "account": null,
  "summary": "Director Teresa DeLuca of Surgery Partners Inc. (SGRY) acquired 11,250 shares of the company's common stock on August 18, 2026, for a total of $161,212. The transaction took place at a price of $14.33 per share, resulting in Ms. DeLuca owning a total of 68,093 shares. The stock, currently trading at $13.94, has seen a 7.3% decline over the past week. The amended Form 4 filing, dated August 20, 2026, corrected an earlier report of a purchase of 10,000 shares at $14.35 per share. This move comes as Surgery Partners reports a wider-than-expected loss in its second-quarter 2026 financial results, with adjusted earnings at negative $0.12 per share, while analysts had expected a profit of $0.06 per share. Despite the earnings miss, the company reported revenue of $848.9 million, exceeding the forecast of $830.05 million. The company is undergoing a significant portfolio shift, primarily through the planned sale of two Idaho Falls community hospitals, expected to generate around $795 million. Analysts have reiterated a Buy rating for Surgery Partners with a $24 price target, reflecting confidence in the company's strategic moves.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "5am Partners VII, LLC sells $140,313 of Skye Bioscience stock",
        "url": "https://urgent.news/2026/08/20/5am-partners-vii-llc-sells-140-313-of-skye-bioscience-stock",
        "published": "2026-08-20T23:16:13.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}